Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.53 |
| ▸ | ICMT | O60725 | 5/20 | 0.53 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931405 | 0.93 | ALDH1A1 (0.59) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL8173991 | 0.92 | ALDH1A1 (0.58) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL13931408 | 0.92 | ALDH1A1 (0.58) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL13931407 | 0.92 | ALDH1A1 (0.60) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL8173885 | 0.91 | ALDH1A1 (0.57) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL8171623 | 0.90 | ALDH1A1 (0.64) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL8165182 | 0.89 | ALDH1A1 (0.63) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL8178907 | 0.89 | ALDH1A1 (0.56) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL13931023 | 0.88 | LMNA (0.71) | ALDH1A1LMNAPPARGPPARDPPARA | |
| SCHEMBL8181354 | 0.88 | LMNA (0.62) | ALDH1A1LMNAPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ALDH1A1 1836/4885LMNA 2969/4885PPARG 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.